The ENCHANTMENT HIV Study

Phase 2

Recruiting

• Conditions: Heart Failure With Preserved Ejection Fraction; HIV/AIDS
• Interventions: Drug: Sacubitril-Valsartan 49-51Mg Oral Tablet; Drug: Placebo oral tablet

• Registration Number: NCT04153136
• Lead Sponsor: Massachusetts General Hospital

Brief Summary

Persons with HIV, even those well-treated, are at increased risk for heart disease when compared to the general population. Two hormones called aldosterone and brain natriuretic peptide (BNP), which have been shown to be abnormal in HIV, may be associated with inflammation as well as early changes in structure and function of the heart. This study is being conducted to evaluate whether therapies to block aldosterone and increase BNP levels may reduce the burden and progression of heart failure to improve cardiovascular health.

Detailed Description

This is a 6-month study enrolling persons with HIV with no known history of heart disease. Participants will be screened for early signs of heart failure using cardiac ultrasound (cardiac transthoracic echocardiography or cardiac TTE). Those participants who have early changes in the structure and function of the heart and may be at future risk for heart failure will be enrolled into the study. Additional imaging of the heart will occur using cardiac magnetic resonance imaging (cardiac MRI). Following baseline studies, participants will either receive a medication called sacubitril/valsartan or placebo for 6 months. Sacubitril/valsartan in an FDA approved medication currently being used for heart failure with reduced ejection fraction in the general population, and we are evaluating whether this medication could be useful to reduce HIV-related heart failure with preserved ejection fraction. Sacubitril/valsartan is an oral medication taken twice daily that may block aldosterone hormone and increase natriuretic peptide hormone. Overall, this study aims to investigate the effect of sacubitril/valsartan on measures of heart disease related to inflammation, structure and function of the heart muscle in HIV using cardiac TTE and cardiac MRI imaging as well as blood markers of heart failure and inflammation.

Study Timeline

• Study First Submitted: 2019-10-30
• Study First Submitted QC: 2019-11-03
• Study First Posted: 2019-11-06
• Study Start: 2020-09-11
• Status Verified: 2024-12
• Last Update Submitted: 2024-12-24
• Last Update Posted: 2024-12-27
• Primary Completion: 2025-07-30
• Study Completion: 2025-07-30

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 50

Inclusion Criteria

1. Antiretroviral therapy use for >12 months

2. HIV Viral Load <200 copies/mL

3. Left Ventricular Ejection Fraction>50%

4. Demonstration of one or more criteria for myocardial dysfunction on cardiac transthoracic echocardiogram, relevant to the progression of heart failure with preserved ejection fraction:

   • Left Atrial Volume Index > 28 mL/m2
   • Global Longitudinal Strain <18%
   • Left Ventricular Mass Index > 95g/m2 (female), 115 g/m2 (male)

Exclusion Criteria

1. Known history of congestive heart failure or valvular disease
2. Recent cardiac event or stroke within 3 months
3. Current medication use acting along the RAAS pathway (ACEi, ARB, MR blockade, direct renin inhibitor), potassium (K) supplementation or diuretic
4. Angioedema to ACEi or ARB
5. SBP<100 mmHg
6. Medication suspected to have contraindication with active study drug
7. Steroid use within last 3 months
8. Uncontrolled diabetes requiring insulin and/or HbA1c > 7.5%
9. Creatinine (Cr)>1.5 mg/dL and estimated GFR<60 mL/min/1.73m2
10. K>5.5 mEq/L
11. Hemoglobin <10.0 g/dL
12. Known liver disease or ALT>3x upper limit normal
13. Pregnant, actively seeking pregnancy or breastfeeding
14. Estrogen, progestin derivative, or other sex steroid use within 3 months. Stable physiologic testosterone replacement (> 3 months) is acceptable
15. Current bacterial or other infection
16. Active substance abuse
17. Known reaction to gadolinium

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Sacubitril/Valsartan	Sacubitril-Valsartan 49-51Mg Oral Tablet	Sacubitril/Valsartan 49-51mg twice daily along with lifestyle modification (counseling regarding diet and healthy activity) for 6 months
Placebo	Placebo oral tablet	Placebo twice daily along with lifestyle modification (counseling regarding diet and healthy activity) for 6 months

Primary Outcome Measures

Name	Time	Method
Myocardial Inflammation/Fibrosis	6 months	Myocardial Inflammation/Fibrosis measured by extracellular volume fraction via cardiac magnetic resonance imaging
Myocardial Dysfunction	6 months	Left Atrial Volume Index or Global Longitudinal Strain measured by cardiac transthoracic echocardiography

Secondary Outcome Measures

Name	Time	Method
Other Indices of Myocardial Dysfunction	6 months	Alterations in other cardiac structure and function as measured by cardiac magnetic resonance imaging or cardiac transthoracic echocardiogram
Markers of Myocardial Inflammation and Fibrosis	6 months	Circulating biomarkers of myocardial inflammation and fibrosis: Gal3, ST2, GDF15, hs-cTnT
Cardiac Natriuretic Peptides	6 months	Circulating cardiac natriuretic peptides: ANP, BNP, NT-proBNP

Trial Locations

Locations (1)

Massachusetts General Hospital; 🇺🇸 Boston, Massachusetts, United States